Clinical Trial Update: A Safety Study of LY2886721 Multiple Doses in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety study of LY2886721 with multiple doses in healthy subjects completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LY2886721

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED | Results posted: 2019-07-19